CNI-1493 reduces the incidence of invasive metastases.

<p>Nude mice were implanted with 10⁶ SK-NEP-1 cells in the left kidney and treated with intraperitoneal CNI-1493 (5 mg/kg/day) or vehicle for six weeks. In one replicate, drug and vehicle were delivered via subcutaneous osmotic pump placed at the time of surgery. In another replicate, drug was given via daily intraperitoneal injections. Mice were then sacrificed, lungs were sectioned, stained with hematoxylin and eosin, and examined for metastases with a pediatric pathologist in a blinded fashion. Immunohistochemistry with CD99 confirmed metastases. Metastatic foci were categorized based upon the presence of invasion into lung parenchyma. **p<0.01.